### **Company Overview** Metropolis Healthcare Limited, established in **1981**, is **India’s second-largest diagnostic chain** and a leading pan-India pathology specialist. Under the leadership of **Ms. Ameera Shah**, Executive Chairperson and Promoter, the company has evolved from a local laboratory into a national and international healthcare leader. It operates in **28 Indian states and 7 Union Territories**, with a growing footprint across **over 750 towns in India and Africa**, serving urban, semi-urban, and underserved Tier 2 and Tier 3 geographies. Metropolis maintains a **network of over 220 laboratories, 4,450+ service centers, and more than 10,000 patient touchpoints**, making it one of the most extensive diagnostic networks in the region. The company is **NABL- and CAP-accredited**, maintaining a **CAP proficiency score above 98%** for over a decade—placing it among the **top 1% of laboratories globally** for quality and accuracy. --- ### **Core Business Model and Strategic Pillars** Metropolis follows a **patient-centric, science-led** approach, integrating **technology, innovation, and high-quality diagnostics** to build long-term trust with consumers and clinicians. Its strategic evolution has been guided by three key phases: - **Metropolis 2.0 (2015)**: Focused on scaling B2C operations. - **Metropolis 3.0 (post-2022)**: Centered on **digital transformation**, **scientific innovation**, **geographic expansion**, and **adjacent service integration**. The current strategy is built on **five pillars**: 1. **B2C-led growth** with a goal to increase B2C revenue contribution to **65% in focus cities**. 2. **Expansion into high-value specialty diagnostics**, especially **oncology and genomics**. 3. **Digital transformation and omnichannel engagement** (app, WhatsApp, web). 4. **Inorganic growth via "String of Pearls" acquisitions**. 5. **Geographic consolidation**, especially in **North and East India**. --- ### **Revenue and Segment Mix** - **B2C contributes ~55% of revenue**, with **80–90% of B2C from walk-in patients**, indicating strong brand loyalty. - **B2B and institutional** contribute the remainder, serving hospitals, labs, and corporates. - **Specialty diagnostics account for ~40% of revenue**, though only 15–22% of test volume, highlighting a **high-margin, high-value business model**. - **Wellness (TruHealth)** contributes **~18–26% of test volume** and has grown at **24–26% YoY**, driven by bundled preventive packages. - **Specialty test volumes and revenues grew by 16% YoY**, with oncology as the fastest-growing segment. --- ### **Oncology & Advanced Diagnostics Leadership** Metropolis has positioned itself as **India’s largest oncology testing provider**, primarily through the **strategic acquisition of Core Diagnostics (Feb 2025)**. Key highlights: - Core Diagnostics was a **leading oncology lab** with **1,600+ oncologists, 6,000+ specialists**, and **1,300+ niche tests** (85% focused on oncology and oncogenomics). - Post-acquisition, Metropolis now serves **1,600+ oncologists across India**, with **oncology revenue expected to grow from 4% to 10% of total revenue**. - The acquisition was **EPS accretive from FY26**, with **pro forma EBITDA synergies increasing from Rs. 1.8 Cr to Rs. 3.4 Cr** in Kolhapur due to operational integration. - Metropolis has established a **Center of Excellence in Oncology**, integrating **genomics, molecular oncology, histopathology, and cytogenetics**. - Investments in **Next-Generation Sequencing (NGS), AI-based diagnostics, and India’s largest bio-bank (40,000+ samples)** reinforce its leadership. --- ### **Strategic Acquisitions and “String of Pearls” Growth** Metropolis has completed **over 20 acquisitions**, executing a disciplined **"String of Pearls" strategy** to target **market-leading B2C labs in underpenetrated regions**. Key acquisitions (2024–2025): | **Acquisition** | **Date** | **Key Benefits** | |------------------------|---------------|------------------| | **Core Diagnostics** | Feb 2025 | National oncology leadership, expanded North/East presence, 1,600+ oncologists, EPS accretive | | **Scientific Pathology (Agra)** | Mar 2025 | Regional reference lab in UP, expands B2C reach, now contributes above avg. margins | | **DAPIC (Dehradun)** | Apr 2025 | Strengthens Uttarakhand presence, second-largest chain in the region | | **Ambika Pathology (Kolhapur)** | Aug 2025 | Doubled scale in Western Maharashtra, created largest lab in Kolhapur | - All acquisitions were **strategically selected based on profitability (EBITDA, ROCE), scientific values, and synergies**. - **Synergies are realized through procurement optimization, lab consolidation, digital integration, and cross-selling**. - The company finances acquisitions via **internal accruals** and emphasizes **accrutive, low-risk integration**. --- ### **Network Expansion and Market Penetration** - **Current Network**: 220+ labs, 4,450+ service centers, 750+ towns. - **Target**: Expand to **1,000 towns**, with **400+ new collection centers** in FY25–26, primarily in **Tier 2/3 towns**. - Growth is driven by a **hub-and-spoke model**, enabling **high throughput and faster turnaround**. - Company-owned labs (500+ centers) offer **higher service control and NPS (86%)**, differentiating from franchise-heavy competitors. - A “micro-market” strategy uses **hyper-local campaigns, regional health insights, and clinician engagement** to drive patient acquisition. --- ### **Digital Transformation and Customer Engagement** Metropolis has invested heavily in **AI, automation, and digital platforms** to enhance experience and efficiency: - **Metropolis App**: Offers real-time tracking, personalized health journeys, AI-driven test recommendations, and secure report sharing. - **MetAdvisor**: AI-powered engine for personalized test suggestions, increasing **cross-selling and upselling**. - **MetroBot**: AI WhatsApp chatbot serving **70,000+ clinicians**, providing 24x7 support and query resolution. - **TruHealth Platform**: Bundled packages combining **blood tests, vital checks, ECGs, and doctor consultations**, now accounting for **18% of test volume**. - **Digital Revenue Contribution**: Targeting **33% from D2C channels** over the next 3 years. --- ### **Adjacent Services and Integrated Care** To evolve from a diagnostics player to a **holistic healthcare platform**, Metropolis is piloting: - **Vitals Check**: Blood pressure, BMI, temperature at select centers and home visits. - **Doctor Consultations**: Integrated digitally and in-person. - **Soft Radiology**: X-ray, sonography, ECGs available at **240+ centers** and growing to **3,000 by FY28**. - **Home-based ECG and teleconsultations** now embedded in TruHealth, enhancing patient care cycle. These services **increase “Revenue Per Prescription” (RPP)** and deepen engagement, especially in **preventive and chronic disease management**. --- ### **Competitive Positioning** - **Differentiation**: Quality, scientific excellence, doctor trust, **99% diagnostic accuracy**, and **Indian-specific reference ranges**. - **Competitive Moat**: - High barriers in **oncology diagnostics** (Rx-driven, trust-based, R&D-intensive). - **Digital players** struggle to scale illness-based testing due to **lack of clinician trust**; most remain limited to wellness. - Hospital-based diagnostic chains face **pricing disparities and branding challenges**. - **Market Share**: Leader in **South and West India**, building rapidly in **North and East**.